Methods for treating neuroblastoma
US-2017007599-A1 · Jan 12, 2017 · US
Molecules for administration to ROS1 mutant cancer cells
US10231965B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10231965-B2 |
| Application number | US-201514623904-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2015 |
| Priority date | Feb 20, 2014 |
| Publication date | Mar 19, 2019 |
| Grant date | Mar 19, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 2. A method according to claim 1 , wherein said at least one target gene is ROS1. 3. A method according to claim 1 , wherein said at least one target gene is selected from at least one of NTRK1, NTRK2, and NTRK3. 4. A method according to claim 1 , wherein said cancer is selected from non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer. 5. A method according to claim 4 , wherein said cancer is selected from non-small cell lung cancer, neuroblastoma, and colorectal cancer. 6. A method of treating non-small cell lung cancer in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 7. A method according to claim 1 , wherein said cancer is papillary thyroid cancer. 8. A method according to claim 1 , wherein said cancer is pancreatic cancer. 9. A method according to claim 1 , wherein said cancer is colorectal cancer. 10. A method according to claim 1 , wherein said cancer is mammary analogue secretory carcinoma. 11. A method of treating a sarcoma in a patient, wherein said patient is known to possess at least one genetic alteration in at least one target gene selected from ROS1, NTRK1, NTRK2, and NTRK3, the method comprising administering to said patient a therapeutically effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide, or a pharmaceutically acceptable salt thereof. 12. A method according to claim 6 , wherein said at least one target gene is ROS1. 13. A method according to claim 6 , wherein said at least one target gene is NTRK1. 14. A method according to claim 6 , wherein said at least one target gene is NTRK2. 15. A method according to claim 6 , wherein said at least one target gene is NTRK3. 16. A method according to claim 1 , wherein said at least one target gene is NTRK1. 17. A method according to claim 1 , wherein said at least one target gene is NTRK2. 18. A method according to claim 1 , wherein said at least one target gene is NTRK3. 19. A method according to claim 11 , wherein said at least one target gene is ROS1. 20. A method according to claim 11 , wherein said at least one target gene is selected from at least one of NTRK1, NTRK2, and NTRK3.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for metastasis · CPC title
Antineoplastic agents · CPC title
- A61K31/496Primary
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10231965B2 cover?
- Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
- Who is the assignee on this patent?
- Ignyta Inc, Nerviano Medical Sciences Srl
- What technology area does this patent fall under?
- Primary CPC classification A61K31/496. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).